Beneficial effects of ondansetron as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A double-blind, randomized, placebo-controlled study

Schizophrenia Research

Volumn 88, Issue 1-3, 2006, Pages 102-110

  Zhang, Zhang Jin ^a,b   Kang, Wan Hu ^b   Li, Qiang ^b   Wang, Xue Yi ^b   Yao, Shao Min ^c   Ma, Ai Qun ^c  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b THE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHANDONG MENTAL HEALTH CENTER   (China)

Author keywords

5 HT3 receptor antagonist; Haloperidol; Ondansetron; Schizophrenia

Indexed keywords

HALOPERIDOL; ONDANSETRON; PLACEBO;

ADULT; AGED; AKATHISIA; ANOREXIA; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITAL PATIENT; HUMAN; HYPERACTIVITY; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MUSCLE RIGIDITY; NAUSEA AND VOMITING; PARKINSONISM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALIVATION; SCHIZOPHRENIA; TREMOR; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; SCHIZOPHRENIA;

EID: 33750609681     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.07.010     Document Type: Article

References (34)

1. Abi-Dargham A., Laruelle M., Wong D.T., Robertson D.W., Weinberger D.R., and Kleinman J.E. Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J. Neurochem. 60 (1993) 730-737
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth edition (1994), American Psychiatric Association, Washington, DC
3. Bell M.D., Lysaker P.H., Milstein R.M., and Beam-Goulet J.L. Concurrent validity of the cognitive component of schizophrenia: relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 54 (1994) 51-58
4. Briskin J.K., and Curtis J.L. Augmentation of clozapine therapy with ondansetron. Am. J. Psychiatry 154 (1997) 1171
5. Broocks A., Little J.T., Martin A., Minichiello M.D., Dubbert B., Mack C., Tune L., Murphy D.L., and Sunderland T. The influence of ondansetron and m-chlorophenylpiperazine on scopolamine-induced cognitive, behavioral, and physiological responses in young healthy controls. Biol. Psychiatry 43 (1998) 408-416
6. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 (2001) 518-526
7. Costall B., and Naylor R.J. Pharmacological properties and functions of central 5-HT3 receptors. Therapie 46 (1991) 437-444
8. Costall B., and Naylor R.J. 5-HT3 receptors. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 27-37
9. Daneluzzo E., Arduini L., Rinaldi O., Di Domenico M., Petruzzi C., Kalyvoka A., and Rossi A. PANSS factors and scores in schizophrenic and bipolar disorders during an index acute episode: a further analysis of the cognitive component. Schizophr. Res. 56 (2002) 129-136
10. Elvevag B., and Goldberg T.E. Cognitive impairment in schizophrenia is the core of the disorder. Crit. Rev. Neurobiol. 14 (2000) 1-21
11. Gharabawi G.M., Bossie C.A., Lasser R.A., Turkoz I., Rodriguez S., and Chouinard G. Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia. Schizophr. Res. 77 (2005) 119-128
12. Goff D.C., and Evins A.E. Negative symptoms in schizophrenia: neurobiological models and treatment response. Harv. Rev. Psychiatry 6 (1998) 59-77
13. Guy W. ECDEU Assessment Manual for Psychopharmacology (revised) (1976), US Department of Health, Education, and Welfare, Bethesda, MD
14. Haus U., Spath M., and Farber L. Spectrum of use and tolerability of 5-HT3 receptor antagonists. Scand. J. Rheumatol., Suppl. 119 (2004) 12-18
15. Javitt D.C. Management of negative symptoms of schizophrenia. Curr. Psychiatry Rep. 3 (2001) 413-417
16. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 (1987) 261-276
17. Krausz M. Efficacy review of antipsychotics. Curr. Med. Res. Opin. 18 S3 (2002) 8-12
18. Levkovitz Y., Arnest G., Mendlovic S., Treves I., and Fennig S. The effect of Ondansetron on memory in schizophrenic patients. Brain Res. Bull. 65 (2005) 291-295
19. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., McEvoy J., Perkins D., Sharma T., Zipursky R., Wei H., Hamer R.M., and HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am. J. Psychiatry 160 (2003) 1396-1404
20. Meltzer H.Y. Role of serotonin in the action of atypical antipsychotic drugs. Clin. Neurosci. 3 (1995) 64-75
21. Mohr P.E., Cheng C.M., Claxton K., Conley R.R., Feldman J.J., Hargreaves W.A., Lehman A.F., Lenert L.A., Mahmoud R., Marder S.R., and Neumann P.J. The heterogeneity of schizophrenia in disease states. Schizophr. Res. 71 (2004) 83-95
22. Parker R.M., Barnes J.M., Ge J., Barber P.C., and Barnes N.M. Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J. Neurol. Sci. 144 (1996) 119-127
23. Peuskens J., Demily C., and Thibaut F. Treatment of cognitive dysfunction in schizophrenia. Clin. Ther. 27 Suppl A (2005) S25-S37
24. Potvin S., Stip E., and Roy J.Y. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int. Clin. Psychopharmacol. 18 (2003) 121-132
25. Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P.D., Kopala L., McGorry P.D., Van Hove I., Eerdekens M., Swyzen W., and De Smedt G. Early psychosis global working group: risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am. J. Psychiatry 162 (2005) 947-953
26. Sharma T. Impact on cognition of the use of antipsychotics. Curr. Med. Res. Opin. 18 S3 (2002) s13-s17
27. Sharma T., and Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatr. Clin. North Am. 26 (2003) 25-40
28. Sirota P., Mosheva T., Shabtay H., Giladi N., and Korczyn A.D. Use of the selective serotonin 3 receptor antagonist ondansetron in the treatment of neuroleptic-induced tardive dyskinesia. Am. J. Psychiatry 157 (2000) 287-289
29. Tandon R., and Fleischhacker W.W. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr. Res. 79 (2005) 145-155
30. Waeber C., Hoyer D., and Palacios J.M. 5-hydroxytryptamine3 receptors in the human brain: autoradiographic visualization using [3H]ICS 205-930. Neuroscience 31 (1989) 393-400
31. Waraich P.S., Adams C.E., Roque M., Hamill K.M., and Marti J. Haloperidol dose for the acute phase of schizophrenia. Cochrane Database Syst. Rev. 3 (2002) CD001951
32. White A., Corn T.H., Feetham C., and Faulconbridge C. Ondansetron in treatment of schizophrenia. Lancet 337 (1991) 1173
33. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., and Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 62 (2001) 878-883
34. Zoldan J., Friedberg G., Livneh M., and Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 45 (1995) 1305-1308